|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 59.85 EUR | -0.25% |
|
+0.67% | -4.92% |
| Nov. 18 | Rovi and Roche sign final agreement for manufacture of new medicine | RE |
| Nov. 06 | Spanish stocks - Factors to watch on Nov 6 | RE |
| Capitalization | 3.06B 3.56B 2.87B 2.67B 4.94B 321B 5.37B 33.54B 12.95B 151B 13.37B 13.08B 553B | P/E ratio 2025 * |
24.8x | P/E ratio 2026 * | 18.9x |
|---|---|---|---|---|---|
| Enterprise value | 3.11B 3.62B 2.92B 2.72B 5.02B 326B 5.46B 34.13B 13.18B 154B 13.6B 13.31B 563B | EV / Sales 2025 * |
4.31x | EV / Sales 2026 * | 3.79x |
| Free-Float |
30.8% | Yield 2025 * |
1.51% | Yield 2026 * | 1.76% |
Last Transcript: Laboratorios Farmaceuticos Rovi, S.A.
| 1 day | -0.25% | ||
| 1 week | +0.67% | ||
| Current month | +0.67% | ||
| 1 month | +3.82% | ||
| 3 months | +0.34% | ||
| 6 months | +8.62% | ||
| Current year | -4.92% |
| 1 week | 59 |  | 60.9 |
| 1 month | 53.8 | | 60.9 |
| Current year | 45.52 | | 66.55 |
| 1 year | 45.52 | | 66.55 |
| 3 years | 35.2 | | 94.8 |
| 5 years | 35.2 | | 94.8 |
| 10 years | 10.8 | | 94.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 2007-07-26 | |
| Director of Finance/CFO | - | 2000-12-31 | |
| Chief Tech/Sci/R&D Officer | - | 2013-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | - | 2021-07-16 | |
| Director/Board Member | - | 2007-07-26 | |
| Director/Board Member | - | 2007-07-26 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 0.48% | 154 M€ | +43.31% | - |
| 0.14% | 1,096 M€ | +28.68% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.25% | +0.67% | -6.12% | +62.02% | 3.56B | |
| -0.41% | -6.06% | +22.37% | +173.58% | 905B | |
| -0.27% | -2.41% | +35.05% | +12.95% | 487B | |
| -1.15% | -0.71% | +28.33% | +37.90% | 400B | |
| +0.26% | +1.14% | +21.30% | +0.44% | 330B | |
| +0.58% | -2.73% | +28.01% | +20.71% | 281B | |
| +0.19% | +2.49% | +18.48% | +24.80% | 255B | |
| -1.16% | -4.87% | -3.70% | -9.35% | 248B | |
| +1.24% | -2.33% | -59.84% | -31.25% | 214B | |
| -3.02% | -4.51% | +20.25% | +15.79% | 178B | |
| Average | -0.21% | -1.93% | +10.41% | +30.76% | 330.01B | |
| Weighted average by Cap. | -0.09% | -2.79% | +17.60% | +55.99% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 723M 841M 678M 632M 1.17B 75.73B 1.27B 7.93B 3.06B 35.77B 3.16B 3.09B 131B | 807M 939M 756M 705M 1.3B 84.53B 1.42B 8.85B 3.42B 39.92B 3.53B 3.45B 146B |
| Net income | 124M 144M 116M 108M 199M 12.95B 217M 1.36B 523M 6.12B 540M 528M 22.36B | 159M 185M 149M 139M 257M 16.69B 280M 1.75B 674M 7.88B 696M 681M 28.82B |
| Net Debt | 53.16M 61.84M 49.8M 46.42M 85.73M 5.57B 93.25M 582M 225M 2.63B 232M 227M 9.61B | -100K -116K -93.68K -87.32K -161K -10.47M -175K -1.1M -423K -4.94M -437K -427K -18.08M |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-05 | 59.85 € | -0.25% | 87,177 |
| 25-12-04 | 60.00 € | +0.42% | 80,774 |
| 25-12-03 | 59.75 € | +0.93% | 61,527 |
| 25-12-02 | 59.20 € | -1.33% | 61,649 |
| 25-12-01 | 60.00 € | +0.93% | 122,282 |
Delayed Quote BME, December 05, 2025 at 11:35 am EST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ROVI Stock
Select your edition
All financial news and data tailored to specific country editions
